TFDA passed review on UMSC01 and agreed to perform the Phase I clinical trials
Notice received from Taiwan FDA (TFDA) on March 19, 2020, in which the clinical trial plan of UMSC01 for inspection and registration that applied by Ever Supreme was approved to proceed. Ever Supreme is allowed to implement allogeneic umbilical cord stem cells in the Phase I clinical trials in treating acute ischemic stroke. Ever Supreme had taken another step forward in the field of new drug development.